NCT00033462已完成2 期
A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 78
- 试验地点
- 1
- 主要终点
- Proportion of patients who are progression-free at 24 weeks
研究概览
简要总结
Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib may interfere with the growth of cancer cells and slow the growth of the tumor.
详细描述
PRIMARY OBJECTIVES:
I. To evaluate the proportion of patients with unresectable hepatocellular or biliary carcinoma treated with OSI-774 who are progression-free at 24 weeks.
SECONDARY OBJECTIVES:
I. To evaluate the toxicity profile of this treatment in each of the patient groups.
II. To evaluate the objective response rate of patients with hepatocellular or biliary carcinoma treated with OSI-774.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed hepatocellular carcinoma (HCC) or biliary carcinoma that is surgically unresectable; exception: for surgically unresectable HCC, a hypervascular mass on CT and an AFP > 100ng/mL will suffice as noninvasive diagnostic criteria
- •Measurable disease defined as at least one lesion whose longest diameter can be accurately measured as ≥ 2.0 cm
- •Absolute neutrophil count (ANC) ≥ 1500/mm3
- •PLT ≥ 75,000/mm3
- •Total bilirubin ≤ 2 x upper normal limits (UNL)
- •Serum AST ≤ 3 x UNL
- •Serum ALT ≤ 3 x UNL
- •Serum creatinine ≤ 2 mg/dL
- •Serum albumin ≥ 2.5 g/dL
- •Patients not receiving anticoagulation: INR ≤ 1.5
- •ECOG performance status (PS) 0, 1, or 2
- •Estimated life expectancy ≥ 3 months
- •Capable of understanding the investigational nature, potential risks and benefits of the study and able to provide written informed consent
- •HCC Patients Only: Child-Pugh classification of A or B
- •For patients having prior cryotherapy, radiofrequency ablation, ethanol injection, or photodynamic therapy, the following criteria must be met:
- •> 6 weeks has elapsed since that therapy
- •Indicator lesion(s) is/are outside the area of prior treatment or, if the only indicator lesion is inside the prior treatment area, there must be clear evidence of disease progression associated with that lesion
- •Edges of the indicator lesion are clearly distinct on CT scanning
排除标准
- •Ampulla of Vater tumors
- •Any of the following as this regimen may be harmful to a developing fetus or nursing child:
- •Pregnant women
- •Breastfeeding women
- •Men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.)
- •NOTE: The effects of OSI-774 on the developing human fetus at the recommended therapeutic dose are unknown
- •Any of the following:
- •> 1 prior systemic anticancer therapy; Note: Chemoembolization will be considered as one prior chemotherapeutic regimen.
- •Prior EGFR targeting therapy
- •Nitrosoureas or mitomycin C ≤6 weeks prior to study entry
- •Other chemotherapy ≤4 weeks prior to study entry
- •Immunotherapy ≤ 4 weeks prior to study entry
- •Biologic therapy ≤ 4 weeks prior to study entry
- •Radiation therapy ≤ 4 weeks prior to study entry
- •Prior cryotherapy, radiofrequency ablation, ethanol injection or photodynamic therapy ≤6 weeks prior to study entry
- •Failure to fully recover from adverse effects of prior therapies regardless of interval since last treatment
- •Other concurrent chemotherapy, immunotherapy, radiotherapy, or any other therapy or supportive care considered investigational
- •Major surgery, or significant traumatic injury occurring ≤ 3 weeks prior to planned treatment start date
- •Any of the following:
- •Gastrointestinal tract disease resulting in an inability to take oral medication
- •Requirement for IV alimentation
- •Prior procedures affecting absorption
- •Active peptic ulcer disease
- •History of other malignancy other than hepatocellular or biliary carcinoma within the previous 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma of the cervix
- •Known abnormalities of the cornea such as:
- •History of dry eye syndrome or Sjorgen's syndrome
- •Congenital abnormality (e.g., Fuch's dystrophy)
- •Abnormal slit-lamp examination using a vital dye (e.g., fluorescein, Bengal-Rose)
- •Abnormal corneal sensitivity test (Schirmer test or similar tear production test)
- •Known CNS metastases; NOTE: These patients are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
- •Uncontrolled intercurrent illness including, but not limited to:
- •Ongoing or active infection
- •Symptomatic congestive heart failure
- •Unstable angina pectoris, cardiac arrhythmia
- •Psychiatric illness/social situations that would limit compliance with study requirements
- •HIV-positive patients receiving combination anti-retroviral therapy; NOTE: Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy; these patients are excluded from the study because of possible pharmacokinetic interactions with OSI-774; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
研究组 & 干预措施
Arm I
Experimental
Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
干预措施: erlotinib hydrochloride (Drug)
Arm I
Experimental
Patients receive oral erlotinib once daily. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity.
干预措施: laboratory biomarker analysis (Other)
结局指标
主要结局
Proportion of patients who are progression-free at 24 weeks
时间窗: At 24 weeks
Confidence intervals for the true PFR will be calculated using the methods of Duffy-Santner.
次要结局
- Objective response, defined by the RECIST criteria in terms of tumor/lesion size and change(Up to 3 years)
- Overall survival(Time from registration to death due to any cause, assessed up to 3 years)
- Time to disease progression(Time from registration to documentation of disease progression, assessed up to 3 years)
- EGFR protein levels(Baseline)
- Overall response rate in EGFR positive patients(Up to 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell CancerRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell CancerNCT00060307National Cancer Institute (NCI)40
已完成
1 期
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive MeningiomaAdult Anaplastic AstrocytomaAdult Anaplastic OligodendrogliomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaAdult Grade I MeningiomaAdult Grade II MeningiomaAdult Grade III MeningiomaRecurrent Adult Brain TumorNCT00045110National Cancer Institute (NCI)136
已完成
2 期
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the CervixRecurrent Cervical CancerCervical Squamous Cell CarcinomaNCT00031993National Cancer Institute (NCI)51
已完成
2 期
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung CancerAdenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00087412National Cancer Institute (NCI)65
已完成
2 期
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung CancerNCT00062101National Cancer Institute (NCI)80